References
- Peleg A Y, Woods M L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54: 803–808
- Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52: 893–898
- Klepser M E, Lewis R E. Antifungal pharmacodynamics. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 1st edn, C H Nightingale, T Murakawa, P G Ambrose. Marcel Dekker, New York, NY 2002; 285–301
- Klepser M E, Wolfe E J, Jones R N, Nightingale C H, Pfaller M A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41: 1392–1395
- Klepser M E, Wolfe E J, Pfaller M A. Antifungal pharmacidynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother 1998; 41: 397–401
- Nagata M P, Gentry C A, Hampton E M. Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?. Ann Pharmacother 1996; 30: 811–818
- Groll A H, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher J S, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274–282
- Sawaya B P, Weihprecht H, Campbell W R, Lorenz J N, Webb R C, Briggs J P, et al. Direct vasoconstrictionas a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991; 87: 2097–2107